

Correction: Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis

Rui Wei¹, Mengqin Lv^{1,*}, Fei Li¹, Teng Cheng¹, Zhengzhong Zhang¹, Guiying Jiang¹, Ying Zhou¹, Ruiqiu Gao¹, Xiao Wei¹, Jicheng Lou¹, Xizi Wu¹, Danfeng Luo¹, Xiangyi Ma¹, Jin Jiang², Ding Ma¹ and Ling Xi¹

¹Cancer Biology Research Center, Key Laboratory of The Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

²Department of Molecular Biology, UT Southwestern Medical Center at Dallas, TX, Dallas, USA

* Co-first author

Published:

Copyright: Wei et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during image processing, the migration images in Figure 4A and 4C were incorrectly used, which led to overlapping areas. In addition, in Figure 4E and 4G, the image LEC-VEGF-C in the Figure 4E was mistakenly taken from another experimental group [LEC-CAF/VEGF-C group shown in the Figure 4G]. The corrected Figure 4 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:67315–67328. <https://doi.org/10.18632/oncotarget.18621>




Figure 4: Activation of the Hh signaling pathway in CAFs promotes the migration and capillary tube formation of LECs *in vitro*. (A) and (B) Representative images and statistical analyses of cellular migration of LECs treated with rSHH (1 µg/ml) or ECM. The group with VEGF-C (5 ng/ml) was the positive control. (C) and (D) Representative images and statistical analyses of migration of LECs in a co-culture invasion system with CAFs treated with or without rSHH. The group with VEGF-C (5 ng/ml) was the positive control. (E) and (F) Representative images and statistical analyses of *in vitro* capillary tube formation of LECs treated with rSHH (1 µg/ml) or ECM. LECs treated with VEGF-C (5 ng/ml) was the positive group. (G) and (H) Representative images and statistical analyses of capillary tube formation of LECs treated with supernatants from cultures of CAFs alone or from CAFs treated with rSHH (1 µg/ml). The group with VEGF-C (5 ng/ml) was the positive control. (I) Representative fluorescent images of VEGFR3- (red), PTCH- (red) and DAPI-labelled (blue) LECs. VEGFR3 is the positive marker for LECs as a membranous protein. (J) Western blot analysis of Gli-1 expression in LECs after 48 h treatment with rSHH (1 µg/ml). GAPDH served as the loading control. (K) CCK8 assay detected the growth rate of LECs at 48 h and 72 h after treatment with rSHH at various doses. The data are expressed as the mean ± s.e.m. (***P<0.001, ****P<0.0001).